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Abstract
Objectives To evaluate the cost-effectiveness of insulin degludec (degludec) versus insulin glargine 100 units/mL (glar-
gine U100) in basal–bolus regimens for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk based on the 
DEVOTE CV outcomes trial.
Methods A microsimulation model, informed by clinical outcomes from the subgroup of patients using basal–bolus insulin 
therapy in DEVOTE (NCT01959529) and by the UKPDS Outcomes Model 2 risk equations, was used to model direct costs 
(2018 GBP) and effectiveness outcomes [quality-adjusted life years (QALYs)] with degludec versus glargine U100 over a 
40-year time horizon. The model captured the development of eight diabetes-related complications, death, severe hypogly-
cemia and insulin dosing. This analysis was conducted from the perspective of National Health Service (NHS) England.
Results Treatment with degludec versus glargine U100 in basal–bolus regimens was associated with improved clinical out-
comes at a higher cost per patient [incremental cost effectiveness ratio (ICER): £14,956 GBP/QALY]. Degludec remained 
cost effective versus glargine U100 in all exploratory sensitivity analyses, with ICERs below the widely accepted willingness-
to-pay threshold, although the result was most sensitive to assumptions regarding the persistence of treatment effects.
Conclusions Our long-term modeling analysis suggested that degludec was cost effective (from the perspective of NHS 
England) versus glargine U100 in basal–bolus regimens for patients with T2D at high CV risk. Our findings raise important 
questions regarding how to model the health economics of diabetes therapies.
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Key Points for Decision Makers 
The increasing number of completed cardiovascular 
(CV) outcomes trials provides new opportunities to 
model cost effectiveness based on long-term CV out-
comes data.
We report the first such evaluation for insulin deglu-
dec (degludec) versus insulin glargine 100 units/mL 
(glargine U100) informed by data from a basal–bolus 
subgroup of the DEVOTE CV outcomes trial.
From the perspective of England’s National Health 
Service, lifelong treatment with degludec was cost effec-
tive versus glargine U100 in basal–bolus regimens for 
patients with type 2 diabetes at high CV risk.
Our study raises important questions and makes pro-
posals on how to model and analyze the cost-utility of 
diabetes therapies in the era of CV outcomes trials.
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1 Introduction
Type 2 diabetes (T2D) is a leading cause of morbidity and 
mortality worldwide [1]. The cost of treating diabetes-
related complications is substantial and often far exceeds 
the cost of blood glucose-lowering medications [2]. For 
T2D in the UK, only one-fifth of direct health costs relate to 
diabetes treatment and ongoing management, with the rest 
(80% of costs, estimated at over £7 billion GBP in 2011/12) 
spent treating complications of the disease [3]. The use of 
economic simulation modeling tools to support healthcare 
decision making is widespread and necessary [4]. This is 
particularly true for chronic, progressive diseases such as 
diabetes where the time-horizon of interest for decision mak-
ing is patient lifetime, and hence well beyond the time and 
resource constraints of clinical trials [5].
Epidemiological evidence suggests that T2D is an inde-
pendent risk factor for cardiovascular (CV) disease and 
microvascular complications [6]. Compared with the general 
population, patients with T2D are twice as likely to experi-
ence a CV event, with 60% of patients dying as a result of 
CV disease [7, 8]. Since the US Food and Drug Administra-
tion introduced guidance for industry in 2008 that requires 
an investigation of the CV safety of glucose-lowering medi-
cations, an increasing number of cardiovascular outcomes 
trials (CVOTs) have been conducted [9]. These large-scale 
trials provide a rigorous assessment of the CV safety of 
diabetes therapies in high-risk patient populations, and can 
provide a wealth of useful information and clinical data to 
inform health economic analyses [10]. This raises important 
questions on how to model the health economics of diabetes 
therapies.
Results were recently published from DEVOTE, a 
CVOT that compared the CV safety of insulin deglu-
dec (degludec) with that of insulin glargine 100 units/mL 
(glargine U100) in patients with T2D at high CV risk 
[11]. In DEVOTE, degludec was non-inferior to glargine 
U100 with respect to the incidence of CV events [hazard 
ratio: 0.91 (0.78–1.06)95% CI], whilst patients experienced 
significantly fewer episodes of severe hypoglycemia [rate 
ratio: 0.60 (0.48–0.76)95% CI], at similar levels of glycemic 
control with degludec versus glargine U100 [11]. Prior to 
DEVOTE, evaluations of the cost effectiveness of degludec 
versus glargine U100 captured the effects of hypoglycemia 
rates and insulin dosing over short-term (1-year) time hori-
zons, informed by phase 3 clinical trial data [12–18]. Such 
analyses were restricted to short time horizons because the 
treat-to-target design of trials required by regulatory bod-
ies renders longer-term modeling based on  HbA1c outcomes 
non-informative. A similar approach has been taken based 
on data from DEVOTE, which also had a treat-to-target 
design, but this model captured CV outcomes in addition to 
severe hypoglycemia rates and insulin dosing over a 2-year 
time horizon [19]. DEVOTE provides the opportunity to 
source clinical data for degludec and glargine U100 from a 
single, high-quality source to inform longer-term modeling 
based on CV outcomes.
Patients with T2D receiving basal–bolus therapy tend to 
have advanced disease, and are thus at an increased risk 
of poor clinical outcomes and associated healthcare costs 
[20, 21]. The aim of the present analysis was to develop 
a health economic decision model to evaluate the long-
term cost effectiveness of degludec versus glargine U100 
in basal–bolus regimens from the perspective of National 
Health Service (NHS) England.
2  Methods
2.1  DEVOTE Trial Design
The design and primary results of DEVOTE have been pre-
viously published [11, 22]. In brief, DEVOTE was a dou-
ble-blind, randomized, treat-to-target, active comparator-
controlled CVOT conducted at 438 sites in 20 countries. 
Patients with T2D at high CV risk were randomized 1:1 
to receive degludec (100 units/mL) or glargine U100, both 
in addition to standard care. Patients considered at high 
CV risk and eligible for the trial were aged ≥ 50 years of 
age with one or more coexisting CV or renal condition, or 
aged ≥ 60 years of age with one or more CV risk factors. 
The primary composite outcome in DEVOTE was the first 
occurrence of death from CV causes, non-fatal myocardial 
infarction (MI) or non-fatal stroke [collectively termed a 
major adverse cardiovascular event (MACE)]. Secondary 
endpoints included time from randomization to death from 
any cause, and the incidence and rates of severe hypogly-
cemia, which was defined according to the American Dia-
betes Association definition as requiring the assistance 
of another person to actively administer carbohydrate or 
glucagon or to take other corrective actions [23]. Data on 
non-severe hypoglycemia were not collected. In DEVOTE, 
median exposure time was 1.83 years and median observa-
tion time was 1.99 years [11]. The basal–bolus subgroup of 
DEVOTE (n = 3515) was defined as using bolus insulin (in 
a basal–bolus, premix or bolus-only regimen) at baseline 
before switching basal insulin to (or adding) degludec or 
glargine U100 in a basal–bolus regimen [11]. Clinical out-
comes for the DEVOTE basal–bolus subgroup have been 
previously published [19].
2.2  Model Structure
A Monte Carlo microsimulation model developed in Java 8 
(Oracle Corporation, Redwood Shores, CA) was used to 
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model CV death, non-fatal MI, non-fatal stroke and death 
from other causes (i.e. any cause except for CV disease) 
over a 2-year period based on clinical outcomes from the 
DEVOTE basal–bolus subgroup. UKPDS Outcomes Model 2 
(UKPDS OM2) risk equations [24] were used to model other 
diabetes-related complications over the first 2 years, as well 
as first MACE, death from other causes and other diabetes-
related complications over a subsequent 38-year period (for a 
total time horizon of 40 years). Severe hypoglycemic events 
were modeled based on DEVOTE over the entire 40-year 
time horizon. The model was structured in line with the 
UKPDS Outcomes Model, which is a “probabilistic discrete-
time illness–death model with annual cycles” [25]. Model 
coefficients and equations were internally validated against 
the values reported in the UKPDS OM2 using the Lipids in 
Diabetes Study population (refer to Online resource 1) [24, 
26].  HbA1c and systolic blood pressure progressions were 
based on the panel regression equations from the UKPDS 
Outcomes Model 1 [25], with all other risk factors held con-
stant over time (Online resource 2). The model captured the 
development of eight diabetes-related complications (con-
gestive heart failure, ischemic heart disease, renal failure, 
ulcer and blindness; in addition to first and second events 
for non-fatal MI, non-fatal stroke and amputation), death 
from other causes, severe hypoglycemia, insulin dosing, 
quality-adjusted life expectancy (QALE) and direct medical 
costs with degludec versus glargine U100 (refer to Online 
resource 3 for flowchart of model structure).
The base case analysis was run over a 40-year time hori-
zon and included assumptions regarding the persistence of 
treatment effects (degludec vs glargine U100) observed in 
the DEVOTE basal–bolus subgroup. Differences in the inci-
dence of individual components of first MACE, and death 
from other causes were modeled using the glargine U100 
rates and degludec hazard ratios from DEVOTE in years 1 
and 2 (corresponding to the DEVOTE trial period); all sub-
sequent differences in incidence were dependent exclusively 
on differences in risk arising from the simulated patient-level 
history of events occurring in years 1 and 2. Differences in 
insulin dosing and the incidence of severe hypoglycemia 
were maintained over the full 40-year analysis time horizon.
A patient-level model was selected (as opposed to a 
cohort level model) to allow flexibility in modeling multi-
ple simultaneous disease history states. The present Monte 
Carlo microsimulation model addressed two forms of 
uncertainty: ‘first order’ or Monte Carlo uncertainty was 
minimized by using large numbers of Monte Carlo replica-
tions until mean outcomes were stable, while ‘second order’ 
or parameter uncertainly was captured by sampling from 
normal and lognormal distributions around DEVOTE trial 
outcomes and through the use of UKPDS OM2 risk equa-
tions (estimated model coefficients and confidence intervals 
derived from bootstrapped parameter distributions) [24].
2.3  Model Inputs: Clinical Data
For the glargine U100 arm, within-trial event rates for the 
DEVOTE basal–bolus subgroup were used to model rates of 
severe hypoglycemia, death from CV causes, non-fatal MI 
and non-fatal stroke (Table 1). Time to first non-fatal MI, 
first non-fatal stroke, and death from cardiovascular causes 
were analyzed separately using a Cox proportional-hazards 
regression model to provide a hazard ratio (degludec/glar-
gine U100) for each individual component of the compos-
ite MACE endpoint. The number of severe hypoglycemic 
episodes was analyzed using a negative binomial regres-
sion model with a log-link function and log (duration of 
observation time) as offset. Death from other causes (i.e. 
any cause except for first MACE) was analyzed using a Cox 
proportional-hazards regression model. Regression analyses 
(described above) were conducted as per the prespecified 
primary DEVOTE analyses without additional covariates 
[11]. The resulting rate ratios and hazard ratios were applied 
to the glargine U100 event rates, sampling both from nor-
mal distributions around the glargine U100 event rates and 
lognormal distributions around the rate and hazard ratios to 
derive event rates in the degludec arm (Table 1).
For the glargine U100 arm, mean basal and bolus insu-
lin doses in years 1 and 2 were derived from the DEVOTE 
data, and were taken as the arithmetic mean of the doses at 
baseline and 12 months (for year 1) and at 12 and 24 months 
(for year 2) to provide an estimate of area under the curve. 
End-of-trial glargine U100 doses were used to model the 
doses in year 3 onwards, with basal and bolus dose dif-
ferences maintained over the full time horizon. Estimated 
dose ratios from regression analyses (described below) were 
applied to the glargine U100 values to derive dose inputs 
for the degludec arm (Table 1). Insulin dose was analyzed 
with a mixed model for repeated measures within patients 
using an unstructured residual covariance matrix among vis-
its. Visit interactions with age, dose at baseline, body mass 
index, alternative titration target (yes/no) and treatment were 
included in the model as fixed effect covariates. The model 
did not capture differences in  HbA1c as the treat-to-target 
design of DEVOTE resulted in equivalent changes in  HbA1c 
from baseline to 24 months in the DEVOTE basal–bolus 
subgroup [19].
2.4  Model Inputs: Simulation Cohort
A simulated cohort of 1,000,000 patients in each treatment 
arm was generated based upon the patient demographics, 
baseline risk factors, and complication histories from the 
basal–bolus subgroup of DEVOTE (available in Online 
resource 4).
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2.5  Model Inputs: Costs and Perspective
This analysis was conducted from the perspective of NHS 
England. Treatment unit costs were based on 2018 UK list 
prices (Table 2). In both treatment arms, it was assumed that 
a new needle and self-measured blood glucose test strip were 
used per injection, and that patients administered four injec-
tions per day. Diabetes-related complication and adverse 
event costs were extracted from the literature and inflated 
to 2017 GBP prices (the most recent available year) using 
the hospital and community health services index from the 
Personal Social Services Research Unit [27] (Table 2).
2.6  Model Inputs: Utility, Time Horizon 
and Discounting
Diabetes-related health state utility and disutility values 
were extracted from published sources (Table 2). The simu-
lation was run over a 40-year time horizon, sufficient to cap-
ture lifetime costs and effectiveness outcomes in the simu-
lated patient cohort (mean age at baseline of 65.1 years). 
All future costs and clinical benefits were discounted at an 
annual rate of 3.5% in accordance with the National Institute 
for Health and Care Excellence (NICE) recommendations 
[28].
2.7  Sensitivity Analyses
Exploratory simulations were run varying the discount 
rate, time horizon (2 years), shape of the  HbA1c progres-
sion curve, and with alternative costs or disutilities extracted 
from the literature. Additional sensitivity analyses explored 
the influence of varying assumptions regarding the follow-
ing clinical parameters: abolishing individual effects of 
treatment on CV death, MI, stroke or severe hypoglyce-
mia; extending effects of treatment on MACE by 1–3 years 
beyond the DEVOTE trial period; applying MACE haz-
ard ratios to UKPDS projections of MACE in years 3–40; 
removing effects of insulin dose differences; and removing 
all differences (switch to glargine U100) after 2–10 years.
A probabilistic sensitivity analysis based on Monte Carlo 
simulation with non-parametric bootstrapping was used 
to derive estimates of uncertainty around base case out-
comes based on 1000 iterations of N/50 (i.e. 20,000 where 
N = 1,000,000) patients in each simulation arm. All ‘base-
line’ values (i.e. those in the glargine U100 arm) and disutil-
ity values were sampled from normal distributions, while all 
hazard rate and dose ratios were sampled from lognormal 
distributions. One thousand estimates of incremental costs 
and incremental effectiveness in terms of QALYs were plot-
ted on a cost-effectiveness scatterplot and used to plot a cost-
effectiveness acceptability curve (CEAC). The incremental 
Table 1  Clinical model inputs
CI confidence interval, CV cardiovascular, glargine U100 glargine 100 units/mL, MACE major adverse cardiovascular event, MI myocardial 
infarction, N/A not applicable, SE standard error
a Due to the stochastic nature of the model, estimated values for the degludec arm varied in each simulation
b Composite first MACE primary endpoint, however only the individual components were used in the model
c Previously reported in Pollock et al. [19]
d Includes any deaths that are not from first MACE
Degludec/glar-
gine U100 ratio




First  MACEb,c 0.805 Hazard ratio 0.10 [0.658–0.984] 0.0607 0.0489
 Non-fatal MI 0.679 Hazard ratio 0.15 [0.504–0.914] 0.0292 0.0198
 Non-fatal stroke 0.737 Hazard ratio 0.22 [0.476–1.142] 0.0124 0.0091
 CV death 0.920 Hazard ratio 0.15 [0.676–1.253] 0.0191 0.0176
Severe  hypoglycemiac 0.630 Rate ratio 0.152 [0.468–0.849] 0.0850 0.0536
Death from other  causesc,d 0.766 Hazard ratio 0.192 [0.525–1.116] 0.0179 0.0137
Basal insulin dosec Units per day
Baseline N/A 49.0 49.0
12 months 1.031 Ratio of mean doses 0.016 [1.000–1.064] 65.1 67.1
24 months 1.061 Ratio of mean doses 0.022 [1.016–1.108] 70.4 74.7
Bolus insulin dosec Units per day
Baseline N/A 39.4 39.4
12 months 0.954 Ratio of mean doses 0.024 [0.910–1.000] 59.5 56.8
24 months 0.955 Ratio of mean doses 0.036 [0.891–1.025] 69.7 66.6
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Table 2  Unit costs and utility data
DisU disutility, EQ-5D EuroQol-5D, GBP pounds sterling, Glargine U100 insulin glargine 100 units/mL, HRQoL health-related quality of life, 
IAsp insulin aspart, MI myocardial infarction, MIMS monthly index of medical specialties, SE standard error, SMBG self-measured blood glu-
cose, TTO time trade-off, U utility, UK United Kingdom
a Only applicable to utility values
b Lantus® (in  Solostar® pen): £37.77 GBP for 1500 units
c Insulin degludec (in  FlexTouch® pen): £46.60 GBP for 1500 units
d Insulin aspart (in  FlexPen®): £30.60 GBP for 1500 units
e BD  MicroFine® 5 mm: £9.69 GBP per 100 needles
f SMBG test costs based on the use of one Accu-Chek® Aviva test strip (£16.09 GBP for 50 units) and one Accu-Chek® FastClix lancet (£5.90 
GBP for 204 units) per test
g Inflation-adjusted to 2017 prices using the hospital and community health services index from the Personal Social Services Research Unit [27]. 
SEs cover hospital costs only as SEs for total costs (hospital costs and non-inpatient healthcare costs) were not available. For renal failure, ulcer 
and severe hypo no SEs were available
h Currency converted based on a Euro/GBP exchange rate of 0.6239 correct as of 01 January 2000 (www.oanda .com)
i SEs calculated using this equation (when required information available). SE = (lower 95% confidence limit–upper 95% confidence limit)/
(2 × 1.96); assuming the sampling is normally distributed
j Three level EQ-5D based on TTO elicited by the general UK population
k TTO elicited by the general population from five countries (including the UK)
Parameter Value SE Unit Source HRQoL preference  
elicitation  methoda
Treatment costs (unit price)
Glargine  U100b 0.0252 0 GBP MIMS [31]
Degludecc 0.0311 0 GBP MIMS [31]
IAspd 0.0204 0 GBP MIMS [31]
Needlee 0.0969 0 GBP MIMS [31]
SMBGf 0.3507 0 GBP MIMS [31]
Complication costsg
MI, year 1 7857 1105 GBP Alva et al. [32]
MI, year 2+ 1953 164 GBP Alva et al. [32]
Stroke, year 1 8449 1753 GBP Alva et al. [32]
Stroke, year 2+ 2013 243 GBP Alva et al. [32]
Amputation, year 1 13,103 1924 GBP Alva et al. [32]
Amputation, year 2+ 3642 514 GBP Alva et al. [32]
Blindness, year 1 3365 611 GBP Alva et al. [32]
Blindness, year 2+ 1274 103 GBP Alva et al. [32]
Heart failure, year 1 4462 880 GBP Alva et al. [32]
Heart failure, year 2 + 2617 361 GBP Alva et al. [32]
Ischemic heart disease, year 1 11,376 1545 GBP Alva et al. [32]
Ischemic heart disease, year 2+ 2000 159 GBP Alva et al. [32]
Renal failure, year 1 18,073 0 GBP NHS tariff value [33, 34]
Renal Failure, year 2+ 18,073 0 GBP NHS tariff value [33, 34]
Ulcer, year  1h 2050 0 GBP Ghatnekar et al. [35]
Ulcer, year 2+h 276 0 GBP Ghatnekar et al. [35]
Severe hypoglycemia 427 0 GBP Hammer et al. [36]
Utilitiesi
Base 0.785 0 U Clarke et al. [37] EQ-5Dj
MI − 0.055 0.006 DisU Clarke et al. [37] EQ-5Dj
Stroke − 0.164 0.030 DisU Clarke et al. [37] EQ-5Dj
Amputation − 0.28 0.056 DisU Clarke et al. [37] EQ-5Dj
Blindness − 0.074 0.033 DisU Clarke et al. [37] EQ-5Dj
Heart failure − 0.108 0.031 DisU Clarke et al. [37] EQ-5Dj
Ischemic heart disease − 0.09 0.018 DisU Clarke et al. [37] EQ-5Dj
Renal failure − 0.164 0.015 DisU Wasserfallen et al. [38] EQ-5Dj
Ulcer − 0.17 0.019 DisU Bagust and Beale [39] EQ-5Dj
Severe hypoglycemia − 0.057 0.002 DisU Evans et al. [40] TTOk
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cost-effectiveness ratio (ICER) for degludec versus glargine 
U100 was compared to the widely accepted UK willingness-
to-pay threshold range of £20,000–£30,000 GBP per QALY 
gained [29].
3  Results
3.1  Base Case Analysis
Treatment with degludec was associated with mean 
QALE of 6.8980 years at a mean cost of £47,311 GBP per 
patient, compared with 6.7825 years at a mean total cost of 
£45,582 GBP per patient with glargine U100 (Table 3). 
Bootstrapped 95% CIs and credible intervals around costs 
and QALYs are presented in Online resource 5. Improved 
clinical outcomes with degludec were driven primarily by 
a lower incidence of severe hypoglycemia, CV death and 
death from other causes, and, to a smaller extent, by reduced 
rates of non-fatal stroke and non-fatal MI. Higher acquisi-
tion costs with degludec were partially offset by lower costs 
of non-fatal MI, severe hypoglycemia and non-fatal stroke. 
This yielded an ICER of £14,956 GBP per QALY gained 
with degludec versus glargine U100 (Table 3). The cumula-
tive incidences of diabetes-related complications for each 
simulation arm over the 40-year time horizon are presented 
in Online resource 6.
3.2  Sensitivity Analyses
Degludec remained cost effective versus glargine U100 
in all sensitivity analyses, with ICERs below the widely 
accepted NICE willingness-to-pay lower threshold value 
of £20,000 GBP per QALY (Table 4). Varying model 
assumptions, quality-of-life disutilities, and complication 
cost estimates did not have a large impact on the ICER 
(which remained within £2000 GBP per QALY of the base 
case ICER), with the exception of a 2-year time horizon 
(as opposed to a 40-year time horizon), which saw the 
ICER decrease to £7828 GBP per QALY gained (Table 4).
Most variations in treatment effects had a large influ-
ence on the resulting ICER, except for removing the inter-
arm differences in CV death or bolus insulin dose. The 
ICER increased from the base case (£14,956 GBP per 
QALY) to over £19,000 GBP per QALY when the effect 
of treatment on non-fatal MI, non-fatal stroke or severe 
hypoglycemia was removed, highlighting the importance 
of these clinical parameters to the overall result. In all 
sensitivity analyses where the duration of treatment effects 
was increased beyond the DEVOTE trial period, the ICER 
was lower than the base case, that is, degludec was more 
cost effective relative to glargine U100 (Table 4).
The most substantial change from the base case ICER 
was observed when the basal insulin price difference and 
all treatment effects were abolished after 2 years (i.e. the 
degludec arm switched treatment to glargine U100 after 
the DEVOTE in-trial period) in which the ICER decreased 
to £2292 GBP per QALY, followed by analyses in which 
the basal insulin price difference and all treatment effects 
were abolished after 3, 4 or 5 years. Extending the dura-
tion of treatment effects for MACE events reduced the 
ICER with each additional year of extension, declining 
to £8973 GBP per QALY when applied in years 1–5 (a 
3-year extension from the base case analysis). Similarly, 
incremental reductions in the ICER were observed with 
each additional year in which the MACE hazard ratios 
(observed in the DEVOTE basal–bolus subgroup) were 
applied to UKPDS projections of MACE events (used to 
model event rates in years 3–40 in the base case analysis) 
(Table 4).
Results of the probabilistic sensitivity analysis indicated 
that degludec was associated with QALY gains in this group 
of patients at an increased cost versus glargine U100, with 
the majority of bootstrap samples falling in the Northeast 
quadrant of the cost-effectiveness scatterplot (Fig. 1a). The 
CEAC showed that the likelihood of degludec being cost 
effective was 72.7% and 88.0% at willingness-to-pay thresh-
olds of £20,000 and £30,000 GBP per QALY, respectively 
(Fig. 1b).
4  Discussion
Our long-term modeling analysis demonstrated that, from 
the perspective of NHS England, degludec provides good 
value for money compared with glargine U100 as part of 
basal–bolus insulin therapy in patients with advanced T2D 
at high CV risk. Lifelong treatment with degludec remained 
cost effective versus glargine U100 in all sensitivity analy-
ses, yielding ICERs below the NICE willingness-to-pay 
lower threshold value of £20,000 GBP per QALY. Despite 
the robustness of the overall result supporting the cost 
effectiveness of degludec, sensitivity analyses revealed that 
the ICER was sensitive to variations in a number of model 
parameters (with ICER estimates ranging from £2292 to 
£19,848 GBP per QALY).
The ICER was particularly sensitive to assumptions 
regarding the duration of treatment effects, most notably the 
removal of all differences after 2 years (i.e. the DEVOTE 
in-trial period). This highlights the importance of assump-
tions of this type in long-term health-economic analyses for 
the treatment of chronic and progressive diseases such as 
diabetes. Our base case analysis was highly conservative, 
with the effect of treatment on first MACE presumed not to 
extend beyond the DEVOTE trial period of 2 years. With 
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this treatment effect extended by just one additional year, 
the ICER for degludec versus glargine U100 decreases by 
£3221 GBP per QALY, with further reductions with each 
additional year of extension. With the assumption of life-
time reductions in MACE incidence with degludec versus 
glargine U100, there would be a gain of 0.6832 QALYs and 
a concomitant reduction in the ICER, but only marginally 
over the assumption of a 5-year MACE advantage (Table 4). 
This is likely due to the survivors’ paradox whereby patients 
continue to incur costs while they remain alive. This empha-
sizes the importance of establishing the duration of CV ben-
efits to validate model assumptions and improve the accu-
racy of long-term health-economic predictions for diabetes 
therapies.
Results from a previous short-term (2-year time horizon) 
cost-utility analysis informed by data from the DEVOTE 
basal–bolus subgroup reported that degludec was associated 
with improved clinical outcomes at cost neutrality (no dif-
ference in costs from an NHS England perspective) versus 
glargine U100 in patients with T2D at high CV risk [19]. 
However, it should be noted that prices and unit costs have 
since changed rendering direct comparisons problematic. 
Similarly, a short-term (1-year) cost-effectiveness analysis 
for the treatment of T2D in basal–bolus regimens in the UK 
reported that degludec is a cost-effective treatment versus 
glargine U100, also reporting an ICER below the NICE will-
ingness-to-pay lower threshold value despite only evaluating 
the effects of hypoglycemia and insulin dosing [15].
According to NICE guidance on the methods for health 
technology appraisal, the time horizon for evaluating cost 
effectiveness should be sufficiently long to reflect all impor-
tant differences in costs or outcomes between comparators 
[28].
Table 3  Results of the base case 
analysis
Costs and QALYs are discounted by 3.5%. Baseline QALYs capture life expectancy
GBP pounds sterling, Glargine U100 insulin glargine 100 units/mL, ICER incremental cost-effectiveness 
ratio, MI myocardial infarction, QALY quality adjusted life-year, SMBG self-measured blood glucose
Degludec Glargine U100 Difference (deglu-
dec − glargine 
U100)
Costs (GBP)
Total costs 47,311 45,582 1729
Treatment and SMBG costs 20,214 18,229 1986
Costs of complications
MI 9003 9198 − 196
Stroke 4254 4336 − 81
Hypoglycemia 226 355 − 129
Heart failure 5262 5189 74
Ischemic heart disease 4553 4511 42
Amputation 2670 2653 18
Renal failure 390 386 4
Ulcer 316 312 3
Blindness 421 414 7
Effects
QALYs
Total QALYs 6.8980 6.7825 0.1156
Baseline 8.1018 8.0020 0.0998
MI − 0.2213 − 0.2241 0.0028
Stroke − 0.2863 − 0.2897 0.0034
Hypoglycemia − 0.0299 − 0.0469 0.0170
Heart failure − 0.2112 − 0.2083 − 0.0030
Ischemic heart disease − 0.1516 − 0.1502 − 0.0014
Amputation − 0.1143 − 0.1136 − 0.0007
Renal failure − 0.0035 − 0.0035 − 0.0000
Ulcer − 0.1652 − 0.1632 − 0.0020
Blindness − 0.0205 − 0.0201 − 0.0004
Incremental cost-effectiveness ratio
ICER (Cost/QALY) 14,956
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Table 4  Sensitivity analyses
Variation Parameter(s) in base 
case model
Costs (GBP) QALE (QALYs) ICERb 
(GBP/
QALY)Degludec Glargine U100 Incremental
a Degludec Glargine U100 Incrementala
Base case N/A 47,311 45,582 + 1729 6.8980 6.7825 + 0.1156 14,956
Model assumptions
 No discounting Discounting (3.5%) 63,001 60,563 + 2438 9.1766 9.0144 + 0.1622 15,028
 Discounting (5%) 42,644 41,122 + 1522 6.2232 6.1212 + 0.1020 14,923
 Flat  HbA1c curve Progressions based 
on UKPDS OM1 
equations
47,338 45,622 + 1716 7.0080 6.9025 + 0.1055 16,264
Treatment effects—individual MACE components
 No difference in CV 
death
Applied years 1–2; 
based on UKPDS 
OM2 projections 
years 3+
47,193 45,582 + 1611 6.8779 6.7825 + 0.0954 16,884
 No difference in 
non-fatal MI
47,579 45,582 + 1998 6.8831 6.7825 + 0.1006 19,848
 No difference in 
non-fatal stroke
47,390 45,582 + 1808 6.8771 6.7825 + 0.0946 19,113
Treatment effects—severe hypoglycemia
 No difference Applied years 1–40 47,448 45,582 + 1866 6.8771 6.7825 + 0.0946 19,718
Treatment effects—MACE  eventsc,d
 Extended to year 3 Applied years 1–2 48,352 46,584 + 1769 6.9053 6.7546 + 0.1507 11,735
 Extended to year 4 49,507 47,630 + 1877 6.9316 6.7473 + 0.1843 10,180
 Extended to year 5 50,669 48,747 + 1922 6.9631 6.7488 + 0.2142 8973
Treatment effects—
MACE  eventsc,e
 HRs applied to 
UKPDS projec-
tions year 3
Based on UKPDS 
OM2 projections 
years 3+
47,563 45,582 + 1982 6.9399 6.7825 + 0.1575 12,583
 HRs applied to 
UKPDS projec-
tions years 3–4
47,882 45,582 + 2301 6.9807 6.7825 + 0.1982 11,607
 HRs applied to 
UKPDS projec-
tions years 3–5
48,149 45,582 + 2567 7.0171 6.7825 + 0.2347 10,940
 HRs applied to 
UKPDS projec-
tions years 3–40
51,174 45,582 + 5593 7.4656 6.7825 + 0.6832 8186
No differences (switch to glargine U100)
 After 2 years Treatment with 
degludec or glargine 
U100 in years 1–40
45,747 45,582 + 166 6.8547 6.7825 + 0.0723 2292
 After 3 years 46,063 45,582 + 481 6.8810 6.7825 + 0.0985 4881
 After 4 years 46,239 45,582 + 657 6.8847 6.7825 + 0.1022 6426
 After 5 years 46,372 45,582 + 790 6.8875 6.7825 + 0.1050 7524
 After 10 years 46,797 45,582 + 1215 6.8940 6.7825 + 0.1115 10,893
Treatment effects—
insulin dose
 No bolus dose dif-
ference
Applied years 1–40 47,537 45,582 + 1955 6.8980 6.7825 + 0.1156 16,916
 No basal or bolus 
dose difference
47,084 45,582 + 1503 6.8980 6.7825 + 0.1156 12,998
Input  parametersf




Hammer et al. [36] 47,137 45,310 + 1827 6.8980 6.7825 + 0.1156 15,809
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As diabetes is a chronic and progressive disease, cost-
effectiveness analyses (CEAs) of diabetes interventions 
have traditionally been performed by estimating long-
term costs and effectiveness outcomes as a function of 
differences in glycemic control. However, over at least the 
last decade, most trials in diabetes of glucose-lowering 
therapies (especially of insulins) have employed treat-
to-target protocols, which tend to result in similar  HbA1c 
levels being achieved across comparators. Over the last 
5–10 years, this has in turn led to a substantial increase 
in short-term CEAs based on differences in hypoglycemia 
rates and dosing, under the assumption that there would 
be no differences in diabetic morbidity or mortality rates 
in patients treated to the same  HbA1c target. This approach 
is therefore consistent with the NICE recommendation 
that CEAs over shorter time horizons could be justified if 
there is no differential mortality effect between compara-
tors, and if differences between costs and effectiveness 
outcomes relate to a relatively short period [28]. The find-
ings of several recent CVOTs, in which significant dif-
ferences in the primary endpoints were reported despite 
the use of treat-to-target protocols [30], raises important 
methodological questions about the health-economic 
assessment of diabetes interventions. For instance, in 
the DEVOTE basal–bolus subgroup, there was a signifi-
cantly lower risk of MACE with degludec versus glargine 
U100 at glycemic parity [19]. This finding highlights the 
potential for differential mortality effects between treat-
ment comparators and differential clinical outcomes (and 
associated costs) at equivalent levels of glycemic control, 
and such differences might persist for longer than the 1- to 
2-year time horizons employed in most short-term CEAs 
of diabetes interventions. This can be used as inspiration 
for future evaluations and, potentially, more nuanced guid-
ance regarding model inputs including, but not limited to, 
the time horizon, important clinical and effectiveness out-
comes, and the persistence of treatment effects.
One key limitation of the present analysis was that it 
was conducted in the basal–bolus subgroup of DEVOTE; 
hence, the results cannot necessarily be extrapolated to 
all patient populations. Additionally, as with all modeling 
analyses, the result was dependent on the underlying mod-
eling assumptions, and it can be challenging to make pre-
dictions over longer timeframes. However, the influence of 
Treatment effects refer to clinical model inputs informed by the DEVOTE basal–bolus subgroup for the degludec and glargine U100 treatment 
arms (Table 1). No differences (switch to glargine U100) refers to the removal of all treatment effects and the basal insulin price difference. 
Please refer to Online resource 7 for alternative costs and disutilities
CV cardiovascular, dominant improved quality of life at lower or similar cost, GBP pounds sterling, Glargine U100 glargine 100 units/mL, HR 
hazard ratio, ICER incremental cost-effectiveness ratio, MACE major adverse cardiovascular events, MI myocardial infarction N/A not applica-
ble, QALE quality-adjusted life expectancy, QALY quality-adjusted life year, UKPDS OM1 United Kingdom Prospective Diabetes Study Out-
comes Model 1, UKPDS OM2 United Kingdom Prospective Diabetes Study Outcomes Model 2
a Reported for degludec − glargine U100
b Reported for degludec/glargine U100
c Refers to each individual component of the composite first MACE endpoint (MI, stroke and CV death) in conjunction
d Refers to event rates observed in the glargine U100 arm and estimated in the degludec arm for the DEVOTE basal–bolus subgroup
e Refers to the application of hazard ratios for degludec versus glargine U100 from regression analyses to event rates from UKPDS OM2 projec-
tions (these are consistent across treatment arms in the base case analysis)
f Costs inflated to 2017 GBP using the hospital and community health services index from the Personal Social Services Research Unit [27]
g Annualized disutility of − 0.0118
Table 4  (continued)
Variation Parameter(s) in base 
case model
Costs (GBP) QALE (QALYs) ICERb 
(GBP/
QALY)Degludec Glargine U100 Incremental




Evans et al. [40] 47,311 45,582 + 1729 6.9217 6.8196 + 0.1021 16,927




Alva et al. [32] 43,057 41,267 + 1791 6.8980 6.7825 + 0.1156 15,490
Alternative disutilities
 Sullivan et al. [44] Clarke et al. [37] 47,311 45,582 + 1729 7.5102 7.4002 + 0.1100 15,717
 Palmer et al. [45] 47,311 45,582 + 1729 6.3783 6.2669 + 0.1114 15,521
 Hayes et al. [46] 47,311 45,582 + 1729 7.6093 7.4988 + 0.1105 15,647
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underlying assumptions on the result was investigated in 
exploratory sensitivity analyses. Furthermore, these analy-
ses are derived from a treat-to-target study in which basal 
and bolus insulin doses were titrated to achieve target 
fasting [4–5 mmol/mol (71–90 mg/dL)] and pre-prandial 
[4–7 mmol/mol (71–126 mg/dL)] plasma glucose levels. 
Therefore, the results may not be as relevant to the general 
population where less stringent targets are applied.
Strengths of this modeling analysis include the highly 
conservative assumptions in the base case analysis and 
the estimation of long-term diabetes-related complications 
using the UKPDS OM2 risk equations, which were derived 
from up to 89,760 patient-years of data with a median of 
17.6 years of follow-up per patient [24]. Furthermore, our 
results extend the findings of previous comparative analy-
sis for degludec versus glargine U100 that have evaluated 
Fig. 1  Results of the proba-
bilistic sensitivity analysis. a 
Cost-effectiveness scatterplot. 
b Cost-effectiveness acceptabil-
ity curve. For a, the majority 
of points located in the upper 
right-hand quadrant of the 
plot indicates higher costs and 
improved effectiveness for 
degludec versus glargine U100. 
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cost effectiveness over a short-term (1 or 2 years) time 
horizon to provide information on costs and effects based 
on CV outcomes, severe hypoglycemia and insulin dosing 
from a patient-lifetime perspective.
In conclusion, our analysis demonstrates that over 
patient lifetimes, treatment with degludec versus glargine 
U100 would represent an efficient use of NHS resources 
in patients with T2D at high CV risk. CVOTs such as 
DEVOTE provide valuable information and have the 
potential to transform CEAs of diabetes interventions.
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